MYC and non-small cell lung cancer: A comprehensive review

Kenzerki, Maryam Eftekhari; Ahmadi, Mohsen; Mousavi, Pegah; Ghafouri‐Fard, Soudeh

doi:10.1016/j.humgen.2023.201185

Cited by 1 publication

(1 citation statement)

References 61 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Conversely, the KRAS-STAT3-miR34a mechanism was described specifically in LUAD but likely applies to other KRAS-driven tumors [164]. MYC is also recurrently amplified and overexpressed in NSCLC and CD47 and is a direct target of MYC-driven transcription [162,224,225]. Given that CD47 is expressed in up to 84% of NSCLC, oncogenes are unlikely to account for CD47 upregulation in all cases.…”

Section: Pathways To Cd47 Upregulation In Nsclcmentioning

confidence: 99%

CD47: The Next Frontier in Immune Checkpoint Blockade for Non-Small Cell Lung Cancer

Lau,

Khavkine Binstock,

Thu

2023

Cancers

View full text Add to dashboard Cite

The success of PD-1/PD-L1-targeted therapy in lung cancer has resulted in great enthusiasm for additional immunotherapies in development to elicit similar survival benefits, particularly in patients who do not respond to or are ineligible for PD-1 blockade. CD47 is an immunosuppressive molecule that binds SIRPα on antigen-presenting cells to regulate an innate immune checkpoint that blocks phagocytosis and subsequent activation of adaptive tumor immunity. In lung cancer, CD47 expression is associated with poor survival and tumors with EGFR mutations, which do not typically respond to PD-1 blockade. Given its prognostic relevance, its role in facilitating immune escape, and the number of agents currently in clinical development, CD47 blockade represents a promising next-generation immunotherapy for lung cancer. In this review, we briefly summarize how tumors disrupt the cancer immunity cycle to facilitate immune evasion and their exploitation of immune checkpoints like the CD47–SIRPα axis. We also discuss approved immune checkpoint inhibitors and strategies for targeting CD47 that are currently being investigated. Finally, we review the literature supporting CD47 as a promising immunotherapeutic target in lung cancer and offer our perspective on key obstacles that must be overcome to establish CD47 blockade as the next standard of care for lung cancer therapy.

show abstract